ライフサイエンスコーパス: skin grafting

1 fter simultaneous peptide administration and skin grafting.

2 lass I-disparate bm1 mice 7 d prior to donor skin grafting.

3 Donor-specific tolerance was tested by skin grafting.

4 afts, although incomplete tolerance to donor skin grafting.

5 sured by mixed lymphocyte reaction assay and skin grafting.

6 er DST, and 7, 14, 21, 28, and 75 days after skin grafting.

7 s confirmed by mixed lymphocyte reaction and skin grafting.

8 by the use of CSS together with conventional skin grafting.

9 assisted by tissue-expansion techniques and skin grafting.

10 lysis of graft-infiltrating lymphocytes, and skin grafting.

11 (mHA) of the recipient by means of repeated skin grafting.

12 burn excision and autologous split-thickness skin grafting.

13 eceived a WKY lung transplant 35 days before skin grafting.

14 oantigens after second donor and third-party skin grafting.

15 YAC-1 target cells on day 14 or day 15 after skin grafting.

16 Donor-specific tolerance was tested by skin grafting.

17 well as secondary wound closure by means of skin grafting.

18 We have tested T-cell tolerance by skin grafting.

19 s, and then repair with advancement flaps or skin grafting.

20 Injection of each cell type before skin grafting abolished hemopoietic cell engraftment and

21 lowed until rejection with donor/third-party skin grafting, adoptive transfer, and interleukin 2 infu

22 Tolerance was confirmed by AKR skin grafting after antibody clearance.

23 Swine donors were presensitized by mouse skin grafting and boosted by the injection of mouse cell

24 This neglect of skin grafting and nutritional support resulted in critic

25 arrival, all patients underwent excision and skin grafting and received similar clinical care.

26 h broad clinical implications for allogeneic skin grafting and sepsis.

27 ACS) analysis, and tolerance was assessed by skin grafting, and also by mixed lymphocyte reaction (ML

28 Histology, mixed lymphocyte reaction (MLR), skin grafting, and flow cytometry assessed functional to

29 of cirrhotic rats was assessed by allogeneic skin grafting, and the immune response to transplanted p

30 were collected at various times after mouse skin grafting, and their potential to induce GVHD and to

31 fts from both groups was seen on day 1 after skin grafting, and thereafter the number remained stable

32 A full-thickness skin grafting approach was used to investigate the postn

33 etal muscle transplant (VASM) and autologous skin grafting as rescue therapy for refractory squamous

34 Mixed lymphocyte reaction (MLR) and skin grafting assessed donor-specific tolerance in vitro

35 we describe bone marrow transplantation and skin grafting between WT and KO mice to assess the contr

36 rier, measured by the stringent criterion of skin grafting, can be achieved using a noncytoablative t

37 ance, measured by the stringent criterion of skin grafting, can be induced across a widely disparate

38 MLR and skin grafting confirmed donor-specific tolerance in euth

39 This rejection after repeat donor-specific skin grafting correlated with a decline in the percentag

40 Skin grafting experiments between Snd/Snd and control mi

41 Skin grafting experiments confirmed the stratum corneum

42 Adoptive transfer and skin grafting experiments were conducted to assess wheth

43 ific immune suppression, as indicated by the skin-grafting experiments.

44 Standard skin grafting, flow cytometry (FC), and mixed lymphocyte

45 vivors were tested for tolerance by standard skin grafting from the recipient (LEW), the donor (LBN),

46 A streamlined method of skin grafting in mice is described.

47 onfirmed in all limb-allograft recipients by skin grafting in vivo and by MLR in vitro.

48 immunocompetence were determined by standard skin grafting in vivo and mixed lymphocyte reaction (MLR

49 tantially improve healing quality and reduce skin grafting incidents and thus pave the way for clinic

50 in the antidonor CTLp frequency after donor skin grafting, indicating that a specific defect in the

51 ecific pigmentation in reconstructs used for skin grafting is incompletely understood.

52 Skin grafting, MLR, and flow cytometry revealed that tol

53 cells into malignancy in a regenerated human skin grafting model.

54 Using a skin-grafting model, we demonstrated that IL-17 in HPV16

55 2(b/d)) BMCs on day 7 relative to DBA/2 (D2) skin grafting on day 0.

56 -1, +2, and +5 relative to B10.A (H2k) donor skin grafting on day 0.

57 major histocompatibility complex-mismatched skin grafting on day 0.

58 h lesions > 1.5-mm thick frequently required skin grafting or amputation.

59 participants whose treatment had failed, had skin grafting, or were coinfected with human immunodefic

60 lity of delivering secreted proteins through skin grafting rests upon (i) the strength of the promote

61 Injection of presensitized cells after skin grafting resulted in different outcomes depending o

62 Following skin grafting, splenic chimerism was reduced with differ

63 We report a new skin-grafting strategy that stabilizes the Li metal-liqu

64 ytes form squamous cell carcinomas following skin grafting, these results suggest that in mouse kerat

65 in penile reconstruction are glansectomy and skin grafting to fashion a neoglans in penile cancer and

66 ization to donor can, however, be induced by skin grafting two weeks prior to liver transplantation,

67 Skin grafting unveiled additional defects in GATA-3-null

68 nged compared to normal recipients even when skin grafting was delayed until after rejection of the H

69 B10.D2 skin grafting was performed on day 14.

70 In murine models of MHC mismatched skin grafting, we investigated whether it is feasible to

71 crochimerism and was confirmed by second-set skin grafting with donor skin 100 days after the first g